PreMD Continues Appeals For Expanded Skin Cholesterol Test Indication
This article was originally published in The Gray Sheet
Executive Summary
Toronto-based PreMD is exploring a formal scientific dispute against an FDA decision that its Prevu skin cholesterol test is "not substantially equivalent" to other markers of cardiovascular risk
You may also be interested in...
New Data Supports Broader Clearance For Skin Cholesterol Test, Maker Says
Non-invasive diagnostic test maker PreMD says it has the necessary data to support broader use of its PREVU POC skin cholesterol test in asymptomatic patients
FDA Dispute Panel Rebuffs Cardima’s Catheter A-Fib Claims
An FDA dispute resolution body all but halted Cardima's chances to turn around the fortunes of its Revelation Tx microcatheter NavAblator ablation system April 19, voting 5-0 not to recommend approval of the product
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.